Key facts
- It has raised $23.1M.
- Notable investors include High-Tech Gründerfonds, Kurma Partners, Boehringer Ingelheim Venture Fund, Coparion, Creathor Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Tacalyx
- ·The full record, as it builds
Funding rounds
No funding rounds for Tacalyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tacalyx
Developer of therapeutics designed to target cancer-specific carbohydrate antigens. The company's therapeutics combine the ability to synthesize sufficient amounts of complex structures with analysis and screening capabilities and experience in the successful generation of leads against nonpeptide targets, enabling physicians to implement novel immunotherapies that trigger an anti-cancer response efficiently.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2019
- Employees
- 9
- Website
- tacalyx.com/
- Ownership
- Privately Held (backing)
Tacalyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tacalyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tacalyx in its N-PORT filings yet. We sweep new filings monthly.